Biomarkers of basal cell carcinoma resistance to methyl-aminolevulinate photodynamic therapy.
<h4>Background</h4>Methyl-aminolevulinate photodynamic therapy (MAL-PDT) is an excellent option for the treatment of basal cell carcinoma (BCC). However, up to 25% of cases are resistant to this treatment modality.<h4>Objective</h4>The aim of this study was to identify potent...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0215537 |